RIGEL PHARMACEUTICALS INC (RIGL)
Health Care · Oncology and hematology-focused biopharmaceuticals · NASDAQ
Rigel is a commercial-stage biotech with three FDA-approved, niche oncology/hematology drugs generating strong revenue growth and a clinical pipeline of novel kinase inhibitors for rare blood disorders and cancers.
What RIGEL PHARMACEUTICALS INC does
Rigel Pharmaceuticals is a biotechnology company that develops and commercializes novel therapies for hematologic disorders and cancer. The company focuses on products targeting signaling pathways critical to disease mechanisms, with three FDA-approved products: TAVALISSE (fostamatinib) for chronic ITP, REZLIDHIA (olutasidenib) for relapsed/refractory AML with IDH1 mutation, and GAVRETO (pralsetinib) for RET fusion-positive NSCLC and thyroid cancer. The company also has a clinical development pipeline including R289, a dual IRAK1/4 inhibitor for lower-risk MDS.
Themes: Hematologic oncology / blood disorders, Targeted cancer therapies, SYK inhibitors / kinase inhibitors, Rare blood cancers (ITP, AML, MDS), RET-targeted therapy, IDH1 mutation-driven tumors
Fundamentals
- Price$45.89 as of 2026-08-21 close
- Market cap$857M as of 2026-08-21
- 1-year return+9.3% 2025-08-21 close $41.99 → 2026-08-21 close $45.89
- P/E2.42 as of 2026-08-24
- Net margin+116.3% as of 2026-08-24
- Gross margin+91.4% as of 2026-08-24
- ROE+96.5% as of 2026-08-24
- Debt / equity0.09 as of 2026-08-24
- Revenue growth (YoY)+3.3% as of 2026-08-24
- Revenue CAGR (3y)+34.8% SEC XBRL
- Beta1.20 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How RIGL compares in its sector
- price-to-earnings ratiobottom 10% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How RIGEL PHARMACEUTICALS INC looks technically
RIGEL PHARMACEUTICALS INC (RIGL) is trading 27.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 20 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 27.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +27.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $39.19 | $39.19 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $35.89 | $35.89 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 43.99. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 20 trading days ago — a "golden cross", a bullish long-term signal | 20 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 31.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30) | 66.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($37.70 to $47.34) — its "stochastic" reading is 85 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 85.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $52.05 | $52.05 |
|---|---|---|
| From the 52-week high | it is 11.8% below its 52-week high (its highest price of the past year) | -11.8% |
| Above the 52-week low | it is 83.9% above its 52-week low (its lowest price of the past year) | +83.9% |
| Below the 52-week high | it is 11.8% below its highest point of the past year | 11.8% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $310.00 (set on 2007-12-14) | $310.00 |
| Given back of the 52-week move | over the past year its closes ranged ($25.44 to $50.96), and it has recovered almost all of its fall from last year’s high — 80% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $41.21 to $42.03. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 80.1% |
| From the all-time high | it is 85.2% below its all-time high | -85.2% |
| Nearest price level | it is trading 4.7% above a support level at $43.73 — a price it turned at three times since 2025-08-22, most recently on 2026-08-05. Since 2024-08-21 it has 11 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.7% |
| All-time low | its lowest closing price on record is $0.77 (set on 2024-06-26) | $0.77 |
| Above the all-time low | it is 5859.7% above its all-time low | +5,860% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.06 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.06 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $35.24 and $46.65 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $35.24 – $40.95 – $46.65 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
| Stretch from the 200-day average | it is trading 4.9 daily ranges above its 200-day average price (27.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.98× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 10.1% since the prior reading | +10.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 2.3% above the previous close 43 sessions ago and has not traded back through the level it left behind at 32.91 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.3% |
| Gap filled | a 9.8% gap up opened on 2026-08-05 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 14.4 percentage points (the stock gained 16.7% while the market gained 2.3%) | +14.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 54.1 percentage points (the stock gained 57.2% while the market gained 3.1%) | +54.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 18.3 percentage points (the stock gained 29.4% while the market gained 11.1%) | +18.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 11.2 percentage points (the stock gained 9.3% while the market gained 20.5%) | -11.2% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +17.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 34% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $34.35 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +33.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $42.26 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +8.6% |
Price levels it has turned at before
RIGL last closed at $45.89 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $43.73 | Support | 4.7% below the last close | turned there three times · 2025-08-22 to 2026-08-05 |
| $33.07 | Support | 27.9% below the last close | turned there three times · 2026-02-05 to 2026-05-13 |
| $29.66 | Support | 35.4% below the last close | turned there twice · 2024-11-12 to 2024-12-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $43.99.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $41.49 and $43.99 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.80 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$63.00 range $43.00 – $85.00; median $55.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RIGL
- Consensus EPS estimate$0.9635 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory risk: FDA, EMA, MHRA or other regulatory authorities may make adverse decisions regarding product approvals, commercialization, or ongoing compliance for TAVALISSE, REZLIDHIA, GAVRETO and pipeline products","Commercialization and market adoption risk: Success depends on effective distribution, marketing, and payer acceptance for multiple products in niche oncology/hematology indications","Clinical development risk: R289 and other pipeline programs depend on successful completion of Phase 1b and future Phase 2 studies, with failure to achieve safety/efficacy endpoints or enroll sufficient patients potentially delaying or preventing commercialization"]
What changed in the latest 10-Q
AI-assisted comparison of RIGL's 10-Q filed 2026-05-05 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'agency funding disruptions' in forward-looking statements (filed 2026-05-05)
- Added mention of 'payment for our products' in forward-looking statements risks (filed 2026-05-05)
- Added reference to 'volume of product sales' expectations in forward-looking statements (filed 2026-05-05)
- Added description that TAVALISSE is 'our first FDA-approved product' with emphasis on approval status (filed 2026-05-05)
- Added specific quarterly sales figures: TAVALISSE $37.3 million, REZLIDHIA $8.0 million, GAVRETO $9.6 million for Q1 2026 (filed 2026-05-05)
- Added quarterly comparisons showing 31% increase for TAVALISSE, 31% increase for REZLIDHIA, 7% increase for GAVRETO (filed 2026-05-05)
- Added detail that TAVALISSE increase driven by 'lower revenue reserves' (favorable impact) (filed 2026-05-05)
- Added detailed R289 Phase 1b study enrollment numbers: approximately 86 patients total with specific phase breakdowns (filed 2026-05-05)
- Removed:
- Removed reference to '10-K for the year ended December 31, 2024' and replaced with '10-K for the year ended December 31, 2025 filed with the SEC on March 3, 2026' (filed 2025-11-04)
- Removed reference to 'three and nine months ended September 30, 2025' and replaced with 'three months ended March 31, 2026' (filed 2025-11-04)
- Removed reference to 'Securities Act of 1933, as amended' and replaced with 'Securities Act' only (filed 2025-11-04)
- Removed 'US federal government shutdown' and replaced with 'US federal government shutdowns or agency funding disruptions' (filed 2025-11-04)
- Removed text mentioning 'commercialization, distribution and marketing' and added 'payment for' products (filed 2025-11-04)
- Removed nine-month sales data for all three products (filed 2025-11-04)
- Removed section describing RIPK1 inhibitor program with Lilly partner (filed 2025-11-04)
- Removed detailed description of MDACC collaboration scope and CONNECT Phase 2 trial specifics (filed 2025-11-04)
- Removed section stating 'We began our commercialization and started recognizing revenue from product sales of GAVRETO in late June 2024' (filed 2025-11-04)
- Reworded:
- Changed 'TAVALISSE (fostamatinib disodium hexahydrate) is our first product approved by the FDA' to 'TAVALISSE (fostamatinib disodium hexahydrate) is our first FDA-approved product' (filed 2026-05-05)
- Changed order of geographic references for TAVALISSE from 'Canada, Israel, Japan and Korea' to 'Japan, Korea, Canada and Israel' (filed 2026-05-05)
- Changed 'REZLIDHIA capsules are indicated' to 'REZLIDHIA is our second FDA-approved product indicated' (removing capsule form reference) (filed 2026-05-05)
- Changed 'which we began commercializing on June 27, 2024' to 'which we began commercializing in June 2024' (less specific date) (filed 2026-05-05)
- Changed 'Asset Purchase Agreement' to 'asset purchase agreement' (lowercase) (filed 2026-05-05)
- Changed 'pursuant to an asset purchase agreement entered in February 2024' to 'pursuant to a license and transition services agreement entered in July 2022' for REZLIDHIA (filed 2026-05-05)
- Changed 'We continue to advance' to 'Our development pipeline includes' for R289 description (filed 2026-05-05)
- Changed description from 'We have strategic development collaborations' to 'To expand our evaluation...we have strategic development collaborations' (filed 2026-05-05)
- Removed specific details about MDACC collaboration scope regarding 'AML and other hematologic cancers' (filed 2026-05-05)
- Notes:
- Text for Q1 2026 R289 section appears truncated in newer filing; full enrollment details not fully visible
- Older filing covers nine-month period (Jan-Sep 2025) while newer filing covers three-month period (Jan-Mar 2026), making period-to-period comparisons not directly comparable
- REZLIDHIA agreement description changed significantly between filings - older mentions licensing from Forma while newer specifies 'license and transition services agreement entered in July 2022' suggesting potential document revision
Risk Factors
- Added:
- Added reference to Form 10-K for year ended December 31, 2025 filed March 3, 2026 (newer filing, 2026-05-05)
- Added specification of boxed warnings in safety risk factor: 'including to add new or more significant warnings (including boxed warnings, the FDA's most prominent safety warning)' (newer filing, 2026-05-05)
- Removed:
- Removed reference to Form 10-K for year ended December 31, 2024 filed March 4, 2025 (older filing, 2025-11-04)
- Removed specific historical context: 'While we have substantially increased the size of our organization particularly in our sales force in 2021, we also implemented reductions in workforce particularly in our research and development group in 2021 and 2022.' from growth management risk factor (older filing, 2025-11-04)
- Removed asterisk marking from third-party manufacturing risk factor in newer version (newer filing, 2026-05-05)
- Reworded:
- Changed safety risk factor wording from 'Unforeseen safety issues could emerge with our products that could require us to change the prescribing information to add warnings, limit use of the product' to 'change the prescribing information, including to add new or more significant warnings (including boxed warnings, the FDA's most prominent safety warning), limit use of the product' (2026-05-05)
- Changed 'Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will imp' text appears truncated in newer filing but corresponds to older version text that continues differently (both filings)
- Notes:
- Newer filing text appears truncated at end of growth management risk factor, limiting full comparison of that section
- Older filing marks third-party manufacturing risk with asterisk indicating substantive change from prior 10-K; newer filing does not mark it, suggesting it was already addressed in the 2025 10-K
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($87500) — 1 selling insider
- Last 180 days0 buys · 2 sells ($160425) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-22. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RIGL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding RIGL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,476,658
- Reported value $94,008,842
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RIGL had 3,092,899 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RIGL had 16.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.55 days to cover at the same settlement.
- Reported short interest (shares) 3,092,899
- Short interest (% of shares outstanding) 16.6%
- Prior settlement (shares) 3,157,453
- Reported change -2.04%
- Days to cover (reported) 10.55
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- Roche (RHHBY)
- Eli Lilly (LLY)
- Blueprint Medicines (BPMC)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RIGL vs…
RIGL ranks in…
Frequently asked questions
What does RIGEL PHARMACEUTICALS INC (RIGL) do?
Rigel Pharmaceuticals is a biotechnology company that develops and commercializes novel therapies for hematologic disorders and cancer. The company focuses on products targeting signaling pathways critical to disease mechanisms, with three FDA-approved products: TAVALISSE (fostamatinib) for chronic ITP, REZLIDHIA (olutasidenib) for relapsed/refractory AML with IDH1 mutation, and GAVRETO (pralsetinib) for RET fusion-positive NSCLC and thyroid cancer.
What sector is RIGEL PHARMACEUTICALS INC (RIGL) in?
RIGEL PHARMACEUTICALS INC (RIGL) is classified in the Health Care sector. Its industry is Oncology and hematology-focused biopharmaceuticals. It trades on NASDAQ.
Who are RIGEL PHARMACEUTICALS INC's (RIGL) competitors?
Notable peers of RIGEL PHARMACEUTICALS INC (RIGL) include Amgen, Novartis, Bristol Myers Squibb, Roche and Eli Lilly. This peer set is informational only — not financial advice.
Is RIGEL PHARMACEUTICALS INC (RIGL) overbought or oversold right now?
RIGEL PHARMACEUTICALS INC (RIGL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 67, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RIGL come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.